TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02226757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-trastzumab
Description: Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab
Study: NCT03293407

Intervention type: DRUG
Intervention: Iloprost (Ventavis, BAYQ6256)
Description: Using Breelib device

Intervention type: DEVICE
Intervention: Breelib nebulizer
Description: Used for inhalation of Ventavis
Study: NCT00148642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silver salts coated endotracheal tube
Description: intubation with silver coated tube

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: uncoated endotracheal tube
Description: intubation
Study: NCT02573090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive resin based fissure sealing
Description: The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive resin based restoration
Description: The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
Study: NCT02637609

Intervention type: OTHER
Intervention: Likert Scale
Description: Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.

Intervention type: OTHER
Intervention: Best-Worst Scaling (Case 1)
Description: Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
Study: NCT01909986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]ONO-4053
Description: Single dose \[14C\]ONO-4053
Study: NCT04235088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somatosensory intensive intervention
Description: The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
Study: NCT03994718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The music therapist will work with subjects for up to 60 minutes each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual arts intervention
Description: The visual artist will work with subjects for up to 60 minutes each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative writing intervention
Description: The creative writer will work with subjects for up to 60 minutes each session.
Study: NCT01290562

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: One or more high dose(s) of radiation to treat the tumour.
Study: NCT03401125

Intervention type: OTHER
Intervention: Medical file data collection
Description: The information described in the 'outcome measures' section will be collected from the medical files of the patients.
Study: NCT03271450

Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 90 days)
Description: 90 days
Study: NCT02968771

Intervention type: OTHER
Intervention: Non intervention

Intervention type: OTHER
Intervention: Non intervention
Study: NCT03182478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rothbaum protocol in individual format
Description: 8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rothbaum protocol in group format
Description: 8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
Study: NCT01181297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed Formula with a Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Extensively Hydrolyzed Formula without a Probiotic
Study: NCT01600105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfusion MRI
Description: 1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
Study: NCT05267938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthetic
Description: The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
Study: NCT03271450

Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 180 days)
Description: 180 days
Study: NCT05267938

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Topical Anesthetic
Description: The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Description: After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Local anesthetic
Description: After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
Study: NCT04559997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise+FU
Description: 6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator group Exercise
Description: After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
Study: NCT01878240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVAR without coils embolization/ Coils embolization during EVAR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVAR without coils embolization/ Coils embolization during EVAR
Study: NCT02859454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
Study: NCT03435445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online platform group
Description: The online platform has social network, gamification and short-text sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online platform group
Description: The online platform has social network, gamification and short-text sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online dietitian coaching
Description: Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
Study: NCT03271450

Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 90 days)
Description: 90 days

Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 180 days)
Description: 180 days

Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 270 days)
Description: 270 days

Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 270 days)
Description: 270 days
Study: NCT03435445

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Minimal intervention with four videos with diet, physical activity and behavior change recommendations
Study: NCT00673803

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: cataract surgery with implantation of an IOL

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: cataract surgery with implantation of an IOL
Study: NCT03785808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy (low-carb)
Description: Receive dietary guidelines and recipes and consume a low-carbohydrate diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy (low-fat)
Description: Receive dietary guidelines and recipes and consume a low-fat diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special Diet Therapy (USDA control)
Description: Receive dietary guidelines and recipes and consume USDA control diet
Study: NCT05015244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3T (Tesla) Magnetic Resonance Imaging (MRI)
Description: Neurological evaluation using MRI and neuropsychological tests
Study: NCT00574132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: infusion every 13 weeks for a total of 6 infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: given by infusion every 13 weeks for a total of 6 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 m/kg
Description: infusion every 13 weeks for a total of 6 infusions
Study: NCT02912910

Intervention type: OTHER
Intervention: Nifedipine
Description: patients will be assigned to antihypertensive medications by their physicians in the course of their routine care

Intervention type: OTHER
Intervention: Labetalol
Description: patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
Study: NCT00905697

Intervention type: PROCEDURE
Intervention: Living donor lung transplantation
Description: Living donor lung transplantation
Study: NCT00725569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bellis perennis and Staphysagria (C6)
Description: homeopathic remedy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bellis perennis and Staphysagria (C30)
Description: Homeopathic Remedy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo remedy, identical in size, shape and taste to treatment remedies
Study: NCT04922437

Intervention type: PROCEDURE
Intervention: Native bladder implantation
Description: Continent catheterizable channel implanted in the detrusor of the native bladder

Intervention type: PROCEDURE
Intervention: Enterocystoplasty implantation
Description: Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
Study: NCT01778218

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
Description: An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
Study: NCT04672993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urine collection device for men
Description: Use of urine collection device for men
Study: NCT00836485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen 4.0% Patch
Description: This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control is a placebo patch that contains only the inactive ingredients of ketotifen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.2%
Description: 1 gtt/eye on two separate occasions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: 1 gtt/eye on two separate occasions
Study: NCT01278979

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Objective measurements of perineal tears with Peri-Rule
Description: Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus.

Intervention type: OTHER
Group type: OTHER
Intervention: Visual and digital assessment
Description: Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
Study: NCT02650167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colostrum feeding

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: formula for preterm infants
Study: NCT01641081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate in the Pressair DPI, Low Dose
Description: Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate in the Pressair DPI, High Dose
Description: Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil Aerolizer, Low Dose
Description: Foradil Aerolizer 12 micrograms, twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil Aerolizer, High Dose
Description: Foradil Aerolizer 24 micrograms, twice per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in the Pressair for 14 days
Study: NCT03011775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg Tablet
Description: Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate 10Mg Tablet
Description: 1-2 tablets 2 times a day

Intervention type: DRUG
Group type: OTHER
Intervention: Isosorbide Dinitrate 10Mg Tablet
Description: 1-2 tablets 2 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 75Mg Tablet
Description: 1 tablet per a day

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylsalicylic Acid 75Mg Tablet
Description: 1 tablet per a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate 2.5 MG Oral Tablet
Description: 1 tablet per a day

Intervention type: DRUG
Group type: OTHER
Intervention: Bisoprolol Fumarate 2.5 MG Oral Tablet
Description: 1 tablet per a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Calcium 20 MG Oral Tablet
Description: 1 tablet per a day

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin Calcium 20 MG Oral Tablet
Description: 1 tablet per a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 5 MG
Description: 1 tablet per a day

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril 5 MG
Description: 1 tablet per a day
Study: NCT02035930

Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine
Study: NCT01147367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 month physical activity intervention
Description: 3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
Study: NCT05553262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support as described under 'Arm description'.
Study: NCT02283840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT01603706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echo guided implantation group
Description: Lead placement according echo strain imaging result
Study: NCT03850171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
Study: NCT01149525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 2g oral solution , twice per day (morning/evening), during 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution, twice per day (morning/evening), during 3 months
Study: NCT01720472

Intervention type: GENETIC
Intervention: Biomarker studies
Study: NCT01452191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Briefing Plus facilitation
Description: Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Briefing
Description: Children's centres will receive the Injury Prevention Briefing only.
Study: NCT04092439

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Watermelon Juice
Description: 100% Watermelon Juice
Study: NCT01863901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Cryo-Touch III device
Study: NCT05899894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally Adjusted Ventilatory Assist
Description: NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally Adjusted Ventilatory Assist
Description: NAVA mode will be titrated as per protocol alongside titration of PEEP levels. Peep will be titrated for all NAVA levels in a descending order 10,5,0 NAVA level will be titrated in an ascending order 0.5, 1.0, 1.5, 2.0 at each PEEP level
Study: NCT02296294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elo-mel® (Fresenius Kabi Austria)
Description: an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition Monitoring
Description: BCM measurements every 10 minutes for 6 hours.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Body Composition Monitoring
Description: BCM measurements every 10 minutes for 6 hours.
Study: NCT01885949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: oral